1. Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011; 305: 2080 – 2087.
2. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, et al. Atrial fibrillation: Current knowledge and future directions in epidemiology and genomics. Circulation 2011; 124: 1982 – 1993.
3. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, et al. Absolute and attributable risks of atrial fibril- lation in relation to optimal and borderline risk factors: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 1501 – 1508.
4. Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk fac- tors and atrial fibrillation. Circulation 2017; 136: 583 – 596.
5. Miyazawa K, Ogawa H, Mazurek M, Shantsila E, Lane DA, Wolff A, et al. Guideline-adherent treatment for stroke and death in atrial fibrillation patients from UK and Japanese AF Registries. Circ J 2019; 83: 2434 – 2442.
6. Binici Z, Intzilakis T, Nielsen OW, Køber L, Sajadieh A. Exces- sive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 2010; 121: 1904 – 1911.
7. Himmelreich JCL, Lucassen WAM, Heugen M, Bossuyt PMM, Tan HL, Harskamp RE, et al. Frequent premature atrial con- tractions are associated with atrial fibrillation, brain ischaemia, and mortality: A systematic review and meta-analysis. Europace 2019; 21: 698 – 707.
8. Huang BT, Huang FY, Peng Y, Liao YB, Chen F, Xia TL, et al. Relation of premature atrial complexes with stroke and death: Systematic review and meta-analysis. Clin Cardiol 2017; 40: 962 – 969.
9. Conen D, Adam M, Roche F, Barthelemy JC, Felber Dietrich D, Imboden M, et al. Premature atrial contractions in the general population: Frequency and risk factors. Circulation 2012; 126: 2302 – 2308.
10. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: A selected review. Circulation 2008; 118: 2702 – 2709.
11. Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, et al. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis 2016; 246: 141 – 147.
12. Hisamatsu T, Miura K, Fujiyoshi A, Kunimura A, Ito T, Miyazawa I, et al. Association between excessive supraventricu- lar ectopy and subclinical cerebrovascular disease: A population- based study. Eur J Neurol 2019; 26: 1219 – 1225.
13. Siddiquee AT, Kadota A, Fujiyoshi A, Miyagawa N, Saito Y, Suzuki H, et al. Alcohol consumption and cognitive function in elderly Japanese men. Alcohol 2020; 85: 145 – 152.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499 – 502.
15. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemo- globin Standardization Program values. J Diabetes Investig 2012; 3: 39 – 40.
16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982 – 992.
17. Stein PK, Barzilay JI, Chaves PH, Domitrovich PP, Gottdiener JS. Heart rate variability and its changes over 5 years in older adults. Age Ageing 2009; 38: 212 – 218.
18. Persson AP, Fedorowski A, Hedblad B, Persson M, Juul-Möller S, Engström G, et al. Heart rate and premature atrial contrac- tions at 24 hECG independently predict atrial fibrillation in a population-based study. Heart 2020; 106: 287 – 291.
19. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J Am Coll Car- diol 2014; 63: 2335 – 2345.
20. Fedorowski A, Hedblad B, Engström G, Gustav Smith J, Melander O. Orthostatic hypotension and long-term incidence of atrial fibrillation: The Malmö Preventive Project. J Intern Med 2010; 268: 383 – 389.
21. Lee HJ, Lee SR, Choi EK, Han KD, Oh S. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation. J Am Heart Assoc 2019; 8: e012771.
22. Suzuki S. “Cholesterol paradox” in atrial fibrillation. Circ J 2011; 75: 2749 – 2750.
23. Goonasekara CL, Balse E, Hatem S, Steele DF, Fedida D. Cho- lesterol and cardiac arrhythmias. Expert Rev Cardiovasc Ther 2010; 8: 965 – 979.
24. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829 – 1839.
25. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic syndrome and risk of development of atrial fibrillation: The Niigata preventive medicine study. Circu- lation 2008; 117: 1255 – 1260.
26. Lopez FL, Agarwal SK, Maclehose RF, Soliman EZ, Sharrett AR, Huxley RR, et al. Blood lipid levels, lipid-lowering medica- tions, and the incidence of atrial fibrillation: The atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol 2012; 5: 155 – 162.
27. Nitsch D, Felber Dietrich D, von Eckardstein A, Gaspoz JM, Downs SH, Leuenberger P, et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: Results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006; 21: 935 – 944.
28. Wang TJ, Parise H, Levy D, D’Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471 – 2477.
29. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: Effects of weight loss and exercise. J Am Coll Cardiol 2017; 70: 2022 – 2035.
30. Conen D, Tedrow UB, Cook NR, Buring JE, Albert CM. Birth weight is a significant risk factor for incident atrial fibrillation. Circulation 2010; 122: 764 – 770.
31. Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: A cohort study. Arch Intern Med 2004; 164: 1993 – 1998.
32. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: A prospective study and dose-response meta- analysis. J Am Coll Cardiol 2014; 64: 281 – 289.
33. Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: Effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J 2009; 30: 1113 – 1120.
34. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: Cohort study based on longitudinal data from the Framingham Heart Study. BMJ 2018; 361: k1453.
35. Goette A, Lendeckel U, Kuchenbecker A, Bukowska A, Peters B, Klein HU, et al. Cigarette smoking induces atrial fibrosis in humans via nicotine. Heart 2007; 93: 1056 – 1063.
36. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of atrial fibrillation: A systematic review and meta- analysis of prospective studies. Eur J Prev Cardiol 2018; 25: 1437 – 1451.
37. Walsh CR, Larson MG, Evans JC, Djousse L, Ellison RC, Vasan RS, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2002; 136: 181 – 191.
38. Morseth B, Graff-Iversen S, Jacobsen BK, Jørgensen L, Nyrnes A, Thelle DS, et al. Physical activity, resting heart rate, and atrial fibrillation: The Tromsø Study. Eur Heart J 2016; 37: 2307 – 2313.